These results are consistent with studies using other, less specific VEGFR-3 inhibitors, such as SAR131675 in breast xenograft or syngeneic mouse tumor models (59) and AD0157 (60), which were unable to reach the clinic due to their elevated toxicities. The gene discussed is FLT4; the disease is neoplasm.